DK0752860T3 - Androstaner og pregnaner til allosterisk modulering af GABA-receptor - Google Patents

Androstaner og pregnaner til allosterisk modulering af GABA-receptor

Info

Publication number
DK0752860T3
DK0752860T3 DK95913478T DK95913478T DK0752860T3 DK 0752860 T3 DK0752860 T3 DK 0752860T3 DK 95913478 T DK95913478 T DK 95913478T DK 95913478 T DK95913478 T DK 95913478T DK 0752860 T3 DK0752860 T3 DK 0752860T3
Authority
DK
Denmark
Prior art keywords
androstans
pregnans
gaba receptor
allosteric modulation
receptor
Prior art date
Application number
DK95913478T
Other languages
English (en)
Inventor
Ravindra B Upasani
Haiji Xia
Derk Hogenkamp
Original Assignee
Euro Celtique Sa
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0752860(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa, Cocensys Inc filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK0752860T3 publication Critical patent/DK0752860T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J33/00Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
DK95913478T 1994-02-14 1995-02-14 Androstaner og pregnaner til allosterisk modulering af GABA-receptor DK0752860T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19691994A 1994-02-14 1994-02-14
US34692794A 1994-11-23 1994-11-23
PCT/US1995/001712 WO1995021617A1 (en) 1994-02-14 1995-02-14 Androstanes and pregnanes for allosteric modulation of gaba receptor

Publications (1)

Publication Number Publication Date
DK0752860T3 true DK0752860T3 (da) 2000-11-13

Family

ID=26892391

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00200119T DK1038880T3 (da) 1994-02-14 1995-02-14 Androstaner og pregnaner til allosterisk modulering af GABA-receptor
DK95913478T DK0752860T3 (da) 1994-02-14 1995-02-14 Androstaner og pregnaner til allosterisk modulering af GABA-receptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00200119T DK1038880T3 (da) 1994-02-14 1995-02-14 Androstaner og pregnaner til allosterisk modulering af GABA-receptor

Country Status (18)

Country Link
EP (2) EP1038880B1 (da)
JP (1) JP4066272B2 (da)
KR (1) KR100338287B1 (da)
AT (2) ATE375993T1 (da)
AU (1) AU691905B2 (da)
BR (1) BR9506779A (da)
CA (1) CA2183231A1 (da)
DE (2) DE69518509T2 (da)
DK (2) DK1038880T3 (da)
ES (2) ES2296594T3 (da)
FI (2) FI118008B (da)
GR (1) GR3034810T3 (da)
HK (1) HK1014665A1 (da)
IL (1) IL112638A (da)
NO (1) NO308307B1 (da)
NZ (1) NZ282939A (da)
PT (2) PT1038880E (da)
WO (1) WO1995021617A1 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
EP1449846A1 (en) * 1999-04-29 2004-08-25 Euro-Celtique S.A. 3-alpha Hydroxy-3-beta methoxymethyl-21-heterocycle substituted steriods with anaesthetic activity
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
JP2003518038A (ja) 1999-12-20 2003-06-03 ニコラス, ジェイ カークホフ, 流動床噴霧乾燥によるナノ粒子製造方法
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EP2263675A3 (en) * 2005-06-09 2011-05-18 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2125859B1 (en) * 2006-09-19 2013-05-15 Abbott Products GmbH Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors
JP5386362B2 (ja) 2006-11-21 2014-01-15 ウメクライン アーベー Cns疾患治療用医薬組成物の製造のためのプレグナンおよびアンドロスタンステロイドの使用
ES2589139T3 (es) * 2007-06-15 2016-11-10 Research Triangle Institute Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ2009521A3 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
CN113956315A (zh) 2011-09-08 2022-01-21 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2738526T3 (es) * 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
CN102702126B (zh) * 2012-04-26 2014-08-06 四川大学华西医院 一种可用于麻醉剂的化合物
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
SG11201508550XA (en) 2013-04-17 2015-11-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
SI3021852T1 (sl) * 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
EP3035940B1 (en) * 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SG10201803812TA (en) * 2014-05-29 2018-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
PL3206493T3 (pl) 2014-10-16 2021-01-25 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
SG10202009861SA (en) * 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
LT3224269T (lt) * 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
PL3250210T3 (pl) 2015-01-26 2021-07-26 Sage Therapeutics, Inc. Kompozycje i sposoby leczenia zaburzeń OUN
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
MA54851A (fr) 2015-07-06 2021-12-08 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CA2991311A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE053778T2 (hu) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxiszterinek és ezek alkalmazása
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3481846B1 (en) 2016-07-07 2021-05-12 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
CN116162121A (zh) 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
BR112019006365A2 (pt) 2016-09-30 2019-08-06 Sage Therapeutics Inc oxisteróis substituídos c7 e métodos de utilização dos mesmos
JP2019532079A (ja) 2016-10-18 2019-11-07 セージ セラピューティクス, インコーポレイテッド オキシステロールおよびその使用方法
EP3529257B1 (en) 2016-10-18 2023-05-10 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN112823164A (zh) * 2018-05-04 2021-05-18 阿克罗斯制药公司 神经甾体衍生物和其用途
EP3864022B1 (en) * 2018-10-12 2023-09-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
CN111410673A (zh) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
JP2022516986A (ja) * 2019-01-08 2022-03-03 成都康弘薬業集団股▲フン▼有限公司 ステロイド化合物、その使用、およびその調製方法
CA3124703C (en) * 2019-01-14 2023-10-17 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
KR20220066262A (ko) * 2019-08-07 2022-05-24 상하이 한서 바이오메디컬 컴퍼니 리미티드 스테로이드 유도체 조절제의 염 및 결정형
CN112341511A (zh) * 2019-08-09 2021-02-09 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物及其用途
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022040545A1 (en) * 2020-08-20 2022-02-24 Intra-Cellular Therapies, Inc. Organic compounds
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274179A (en) * 1964-03-19 1966-09-20 Merck & Co Inc 3-haloethynyl-3-hydroxy derivatives of the androstane-17-one and pregnane-20-one series
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
JPH06510999A (ja) * 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規GABA↓aレセプター
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf

Also Published As

Publication number Publication date
NO308307B1 (no) 2000-08-28
FI963174A (fi) 1996-09-25
FI118687B (fi) 2008-02-15
ATE195654T1 (de) 2000-09-15
EP0752860B1 (en) 2000-08-23
WO1995021617A1 (en) 1995-08-17
ES2296594T3 (es) 2008-05-01
PT752860E (pt) 2000-12-29
AU691905B2 (en) 1998-05-28
NO963355L (no) 1996-10-11
DE69535623T2 (de) 2008-07-24
FI20051271A (fi) 2005-12-09
FI118008B (fi) 2007-05-31
GR3034810T3 (en) 2001-02-28
ES2151593T3 (es) 2001-01-01
ATE375993T1 (de) 2007-11-15
NO963355D0 (no) 1996-08-12
DK1038880T3 (da) 2008-03-03
DE69518509D1 (de) 2000-09-28
JP4066272B2 (ja) 2008-03-26
EP0752860A1 (en) 1997-01-15
EP1038880A2 (en) 2000-09-27
PT1038880E (pt) 2008-01-29
CA2183231A1 (en) 1995-08-17
IL112638A0 (en) 1995-05-26
HK1014665A1 (en) 1999-09-30
EP1038880B1 (en) 2007-10-17
KR100338287B1 (ko) 2002-11-30
NZ282939A (en) 1998-08-26
EP1038880A3 (en) 2003-07-16
JPH09510701A (ja) 1997-10-28
FI963174A0 (fi) 1996-08-13
AU2090195A (en) 1995-08-29
IL112638A (en) 2003-10-31
DE69535623D1 (de) 2007-11-29
DE69518509T2 (de) 2001-04-19
BR9506779A (pt) 1997-10-14
EP0752860A4 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
DK0752860T3 (da) Androstaner og pregnaner til allosterisk modulering af GABA-receptor
MX9703826A (es) Androstano y series del pregnano para la modulacion alosterica del receptor gaba.
ATE194287T1 (de) Gaba-rezeptor-modulatoren
DK161241C (da) Apparat til fremskyndelse af saarheling
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
DK691587A (da) Apparat og fremgangmsaade til maaling af stroemningsparametre for flerfaset fluidum saasom raaolie
DK97283D0 (da) Fremgangsmade til fremstilling af derivater af 1,2,4-triaziner og - pyridiner
DE59705110D1 (de) Fluoreszenzkorrelationsspektroskopiemodul für ein mikroskop
DE69718441D1 (de) Temperaturreguliervorrichtung für flüssigkeiten
AR020191A1 (es) Aparato y metodo para medir amoniaco en procesos bioquimicos
DK160432C (da) Apparat til reformering af braendselsolie
DK10988A (da) Apparat til dosering af kondenseret gas
DK355185D0 (da) Fremgangsmaade til regulering af en asfaltemulsions viskositet
DK112581A (da) Apparat til regulering af et endeloest,fleksibelt element
DK214881A (da) Indretning til styring af dentale instrumenter
DK266884D0 (da) Gasreguleringsindretning isaer til regulering af gasstroemmen fra gas-eengangsdaaser
DK395982A (da) Apparat til biokemisk bestemmelse af efter hinanden foelgende proever
BR0205208A (pt) Aparelhagem e método para amostragem automática e isocinética de fluidos em escoamento
ATE289527T1 (de) Flüssigkeitsverteiler